Drug
Deferitazole clinical trials
Also written SPD602 and SSP-004184SS.
Includes 2 studies of Deferitazole magnesium.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
14 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses deferitazole is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)CompletedPhase 1ShireNCT01905540Written as SSP-004184AQ
- Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver FunctionCompletedPhase 1ShireNCT01732263Written as SSP-004184
- Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation TherapyTerminatedPhase 2ShireNCT01604941Written as SPD602
- Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)TerminatedPhase 2ShireNCT01671111Written as SSP-004184AQ
- Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult SubjectsCompletedPhase 1ShireNCT01989169Written as SSP-004184SS
- AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184CompletedPhase 1ShireNCT01824446Written as Radiolabeled SPD602 (FBS0701, SSP-004184)
- Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult SubjectsCompletedPhase 1ShireNCT01979185Written as SSP-004184SS
- The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult SubjectsCompletedPhase 1ShireNCT01905553Written as SSP-004184SS
- Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron OverloadTerminatedPhase 2ShireNCT01363908Written as SPD602
- Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal FunctionCompletedPhase 1ShireNCT01716455Written as SSP-004184
- Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron OverloadCompletedPhase 2ShireNCT01186419Written as SPD602 (FBS0701, SSP-004184)
- Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)WithdrawnPhase 1ShireNCT02065401Written as Deferitazole (disodium salt, granule)
- Treatment of Iron Overload Requiring Chelation TherapyWithdrawnPhase 2ShireNCT01927913Written as SPD602
- Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron OverloadCompletedPhase 1FerroKin BioSciences, Inc.NCT01039636Written as FBS0701
Codes
What other systems call deferitazole · ClinicalTrials.gg INT006076
- UNII (FDA) 4D8DC53Y1LDEFERITAZOLEConfirmed FDA, Wikidata
- Wikidata Q27259438deferitazoleConfirmed FDA, Wikidata
- NCI Thesaurus C166753DeferitazoleOne source FDA
- DrugBank DB13120One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4D8DC53Y1L | DEFERITAZOLE | Confirmed FDA, Wikidata |
| Wikidata | Q27259438 | deferitazole | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166753 | Deferitazole | One source FDA |
| DrugBank | DB13120 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.